eLife (Aug 2020)
Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei
- Ali H Alghamdi,
- Jane C Munday,
- Gustavo Daniel Campagnaro,
- Dominik Gurvic,
- Fredrik Svensson,
- Chinyere E Okpara,
- Arvind Kumar,
- Juan Quintana,
- Maria Esther Martin Abril,
- Patrik Milić,
- Laura Watson,
- Daniel Paape,
- Luca Settimo,
- Anna Dimitriou,
- Joanna Wielinska,
- Graeme Smart,
- Laura F Anderson,
- Christopher M Woodley,
- Siu Pui Ying Kelly,
- Hasan MS Ibrahim,
- Fabian Hulpia,
- Mohammed I Al-Salabi,
- Anthonius A Eze,
- Teresa Sprenger,
- Ibrahim A Teka,
- Simon Gudin,
- Simone Weyand,
- Mark Field,
- Christophe Dardonville,
- Richard R Tidwell,
- Mark Carrington,
- Paul O'Neill,
- David W Boykin,
- Ulrich Zachariae,
- Harry P De Koning
Affiliations
- Ali H Alghamdi
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Jane C Munday
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Gustavo Daniel Campagnaro
- ORCiD
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Dominik Gurvic
- Computational Biology Centre for Translational and Interdisciplinary Research, University of Dundee, Dundee, United Kingdom
- Fredrik Svensson
- IOTA Pharmaceuticals Ltd, St Johns Innovation Centre, Cambridge, United Kingdom
- Chinyere E Okpara
- Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
- Arvind Kumar
- Chemistry Department, Georgia State University, Atlanta, United States
- Juan Quintana
- School of Life Sciences, University of Dundee, Dundee, United Kingdom
- Maria Esther Martin Abril
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Patrik Milić
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Laura Watson
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Daniel Paape
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Luca Settimo
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Anna Dimitriou
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Joanna Wielinska
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Graeme Smart
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Laura F Anderson
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Christopher M Woodley
- Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
- Siu Pui Ying Kelly
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Hasan MS Ibrahim
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Fabian Hulpia
- ORCiD
- Laboratory for Medicinal Chemistry, University of Ghent, Ghent, Belgium
- Mohammed I Al-Salabi
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Anthonius A Eze
- ORCiD
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Teresa Sprenger
- Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
- Ibrahim A Teka
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Simon Gudin
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- Simone Weyand
- Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
- Mark Field
- School of Life Sciences, University of Dundee, Dundee, United Kingdom; Institute of Parasitology, Biology Centre, Czech Academy of Sciences, Ceske Budejovice, Czech Republic
- Christophe Dardonville
- Instituto de Química Médica - CSIC, Madrid, Spain
- Richard R Tidwell
- Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
- Mark Carrington
- ORCiD
- Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
- Paul O'Neill
- Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
- David W Boykin
- Chemistry Department, Georgia State University, Atlanta, United States
- Ulrich Zachariae
- Computational Biology Centre for Translational and Interdisciplinary Research, University of Dundee, Dundee, United Kingdom
- Harry P De Koning
- ORCiD
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
- DOI
- https://doi.org/10.7554/eLife.56416
- Journal volume & issue
-
Vol. 9
Abstract
Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common ancestor aquaporin. We demonstrate that TbAQP2’s unique architecture permits pentamidine permeation through its central pore and show how specific mutations in highly conserved motifs affect drug permeation. Introduction of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally strictly impermeable for ionic species. We also identify the structural determinants that make pentamidine a permeant although most other diamidine drugs are excluded. Our results have wide-ranging implications for optimising antitrypanosomal drugs and averting cross-resistance. Moreover, these new insights in aquaporin permeation may allow the pharmacological exploitation of other members of this ubiquitous gene family.
Keywords